罗氟司特在皮肤科的应用：一种新型磷酸二酯酶-4抑制剂 - Suppr

Suppr

超能文献

Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor.

作者信息

Singh Suvesh, Paul Debopriya, Snehal Aditi

机构信息

From the Department of Dermatology, AIIMS, Patna, Bihar, India E-mail:

出版信息

Indian J Dermatol. 2025 Jan-Feb;70(1):38-41. doi: 10.4103/ijd.ijd_261_24. Epub 2024 Dec 30.

DOI:10.4103/ijd.ijd_261_24

PMID:39896310

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11784981/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81c8/11784981/395c51a4d80d/IJD-70-38-g001.jpg

相似文献

Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor.罗氟司特在皮肤科的应用：一种新型磷酸二酯酶-4抑制剂

Indian J Dermatol. 2025 Jan-Feb;70(1):38-41. doi: 10.4103/ijd.ijd_261_24. Epub 2024 Dec 30.

[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.[翻译文章] 皮肤病学中局部和口服罗氟司特：一篇叙述性综述。

Actas Dermosifiliogr. 2024 Mar;115(3):T265-T279. doi: 10.1016/j.ad.2024.01.009. Epub 2024 Jan 13.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.罗氟司特：首个获批用于治疗慢性阻塞性肺疾病的磷酸二酯酶4抑制剂。

Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.罗氟司特的临床前药理学——一种用于慢性阻塞性肺疾病的选择性、口服磷酸二酯酶 4 抑制剂。

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7.

Phosphodiesterase 4 Inhibitor Roflumilast Protects Rat Hippocampal Neurons from Sevoflurane Induced Injury via Modulation of MEK/ERK Signaling Pathway.磷酸二酯酶4抑制剂罗氟司特通过调节MEK/ERK信号通路保护大鼠海马神经元免受七氟醚诱导的损伤。

Cell Physiol Biochem. 2018;45(6):2329-2337. doi: 10.1159/000488180. Epub 2018 Mar 13.

Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.磷酸二酯酶-4 抑制剂罗氟司特减轻肺空气栓塞诱导的肺损伤。

J Surg Res. 2019 Sep;241:24-30. doi: 10.1016/j.jss.2019.03.028. Epub 2019 Apr 17.

Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.罗氟司特，一种磷酸二酯酶-4 抑制剂，通过抗炎作用改善高氧诱导的肺损伤。

Undersea Hyperb Med. 2020 Second Quarter;47(2):189-196. doi: 10.22462/04.06.2020.3.

Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.磷酸二酯酶-4抑制剂罗氟司特对大鼠缺氧和野百合碱诱导的肺动脉高压的影响。

J Pharmacol Exp Ther. 2009 Jul;330(1):54-62. doi: 10.1124/jpet.108.148742. Epub 2009 Apr 22.

Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.罗氟司特 0.3% 乳膏：用于治疗慢性斑块状银屑病的磷酸二酯酶 4 抑制剂。

Am J Ther. 2023;30(6):e535-e542. doi: 10.1097/MJT.0000000000001678.

The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.磷酸二酯酶4抑制剂罗氟司特对精神分裂症脑电图生物标志物的影响：一项随机对照试验。

J Psychopharmacol. 2021 Jan;35(1):15-22. doi: 10.1177/0269881120946300. Epub 2020 Aug 27.

本文引用的文献

Phosphodiesterase-4 Inhibition in the Management of Psoriasis.磷酸二酯酶-4抑制剂在银屑病治疗中的应用

Pharmaceutics. 2023 Dec 22;16(1):23. doi: 10.3390/pharmaceutics16010023.

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.罗氟司特泡沫 0.3%治疗青少年和成年脂溢性皮炎患者的随机、双盲、赋形剂对照、3 期临床试验。

J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20.

[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.[翻译文章] 皮肤病学中局部和口服罗氟司特：一篇叙述性综述。

Actas Dermosifiliogr. 2024 Mar;115(3):T265-T279. doi: 10.1016/j.ad.2024.01.009. Epub 2024 Jan 13.

ZORYVE (Roflumilast) Cream: A Topical Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis.佐立维（罗氟司特）乳膏：一种用于治疗银屑病的外用磷酸二酯酶-4抑制剂。

Skinmed. 2023 Nov 10;21(5):357-359. eCollection 2023.

Topical Roflumilast for Plaque Psoriasis.局部用罗氟司特治疗斑块状银屑病。

Skin Therapy Lett. 2023 Sep;28(5):1-4.

Topical and Oral Roflumilast in Dermatology: A Narrative Review.局部用和口服罗氟司特在皮肤科的应用：综述。

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).口服罗氟司特治疗中重度银屑病的疗效和安全性——一项随机对照试验（PSORRO）

Lancet Reg Health Eur. 2023 Apr 21;30:100639. doi: 10.1016/j.lanepe.2023.100639. eCollection 2023 Jul.

Topical roflumilast for the treatment of psoriasis.外用罗氟司特治疗银屑病。

Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1053-1062. doi: 10.1080/1744666X.2023.2219897. Epub 2023 May 30.

Refractory Behçet disease succesfully treated with roflumilast.用罗氟司特成功治疗难治性白塞病。

Clin Exp Dermatol. 2023 Aug 25;48(9):1060-1062. doi: 10.1093/ced/llad189.

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.罗氟司特泡沫 0.3%治疗脂溢性皮炎患者的疗效：一项双盲、安慰剂对照的 2a 期随机临床试验。

JAMA Dermatol. 2023 Jun 1;159(6):613-620. doi: 10.1001/jamadermatol.2023.0846.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验